EBS) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short. Based on the recent average volume of 1.40M ...
2025 Q1 Revenue Guidance: $200 million to $240 million. Emergent BioSolutions Inc (NYSE:EBS) completed the stabilization phase of their multi-year transformational plan ahead of schedule ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback